Navigation Links
Further Analysis From ATHENA Study Showed That Multaq(R)(Dronedarone) Reduced the Risk of Stroke in Patients With Atrial Fibrillation
Date:9/2/2008

PARIS, September 3 /PRNewswire-FirstCall/ --

- This Analysis Showed That Multaq(R) (Dronedarone) Decreased the Risk of Stroke by 34% in Patients With Atrial Fibrillation or Atrial Flutter Already Adequately Treated by Antithrombotic Therapy

The results of a post-hoc analysis of the data from the ATHENA study were presented today at the clinical trial update session of the European Society of Cardiology congress 2008, in Munich, Germany. Previous results from the landmark ATHENA study have shown that the investigational medicine Multaq(R) (dronedarone) on top of standard therapy decreased the combined primary endpoint of the risk of cardiovascular hospitalisations or death from any cause by a statistically significant 24% (p=0.00000002) as compared to placebo.

The ATHENA stroke post-hoc analysis on non-pre-specified secondary endpoints showed that Multaq(R) decreased the risk of stroke (ischemic or haemorrhagic) compared to placebo by 34% (46 vs 70 stroke events respectively; p=0.027) in atrial fibrillation / atrial flutter patients adequately treated by standard therapy including antithrombotics.

The significant reduction in stroke risk with Multaq(R) was incremental to background anti-thrombotic therapy like oral anticoagulants and / or anti-platelet agents. Similar to the ATHENA primary endpoint of CV hospitalizations or death, this effect appeared early and was maintained during the study follow-up (12 to 30 months).

"ATHENA is a landmark trial that will lead to a paradigm shift in the management of atrial fibrillation as it is the first time that an anti-arrhythmic drug has shown a significant impact on cardiovascular outcomes. As stroke is one of the leading complications of atrial fibrillation, and a major cause of death and long-term disability, these new results demonstrate the unique profile of Multaq(R) beyond its pure rhythm and rate-controlling effects," said Professor Stuart Connolly, Mc Master University, Depar
'/>"/>

SOURCE Sanofi-aventis
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Intercell Announces Initiation of Further Phase II Clinical Trial of V710 an Investigational Vaccine to Prevent S. aureus Infection
2. Addrenex Pharmaceuticals New Hires Further Company Goal to Identify New Drugs for Adrenergic Regulation
3. Blood Pressure Lowering Effect of Hypertension Treatment Device Further Validated in New Studies
4. Published Guidelines Further Support Use of Bioimpedance Measurement Technology for Early Assessment of Lymphedema
5. Further Clinical Testing of BZL101 in Advanced Breast Cancer Demonstrates Favorable Efficacy and Toxicity Profiles
6. QuatRx Pharmaceuticals Announces Presentation of Further Data from Ophena(TM) (Ospemifene) Phase 3 Study for Treatment of Symptoms of Vulvovaginal Atrophy
7. New Roche Data to be Presented at ASCO Offers Further Hope for Cancer Patients
8. Roche Exercises its Option to Further Develop and Commercialize Memory Pharmaceuticals Nicotinic Alpha-7 Agonist, MEM 3454
9. GlaxoSmithKline Reports Further Progress of Oncology Portfolio
10. Arpida Provides Further Comments on the Pivotal Phase III Trials
11. Molecular Science Could Further Improve Leukemia Survival, Say St. Jude Researchers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... WORTH, Texas , Jan. 15, 2014  Humberto C. ... Dermatology Achievement Award" from the Journal of Drugs ... Aesthetic & Clinical Conference (ODAC). The event is January 17-20, ... Florida . The ODAC ...
(Date:1/15/2014)... MultiCell Technologies, Inc. (OTC Bulletin Board: MCET.OB ... composition of matter, biological targets, mechanism of action, methods ... This patent application describes a novel class ... which interfere with the basic homeostatic cellular processes in ...
(Date:1/15/2014)... , Jan. 15, 2014 Reportlinker.com announces ... available in its catalogue: ... Forecast and Market Analysis to 2022 ... Atopic Dermatitis - India Drug Forecast and ...
Breaking Medicine Technology:Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 2Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 3Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 4MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 2MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 2PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 4PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 5
... YORK, Oct. 26, 2011 One week after a ... most serious of skin cancers, which causes 8,000 U.S. ... Skin Association (ASA), a collaboration of patients, families, advocates, ... scientists who have made groundbreaking discoveries and unique contributions ...
... Perrigo Company (Nasdaq: PRGO;TASE) today announced that its ... $0.08 per share, payable on December 13, 2011 ... Perrigo Company is a leading global ... and generic prescription (Rx) pharmaceuticals, infant formulas, nutritional ...
Cached Medicine Technology:American Skin Association Honors Leading Physicians and Scientists; Journalist Deborah Norville 2American Skin Association Honors Leading Physicians and Scientists; Journalist Deborah Norville 3
(Date:7/9/2014)... in Russia might contribute to HIV transmission and ... researchers from Boston University Schools of Medicine and ... State University, sought to discover the effect police ... cohort of HIV-positive people with lifetime of injection ... police were more likely to share needlesincreasing HIV ...
(Date:7/9/2014)... news release is available in French . ... factors in 14 year old teens, including brain structure and ... 70% accuracy who will go on to develop binge drinking ... of conscientiousness, and other variables such as life events and ... of binge drinking. Whether or not the child had ...
(Date:7/9/2014)... extinctions around the world have been linked to ... research from the National Institute for Mathematical and ... may also contribute. , In a series ... causes severe hemorrhage of internal organs in frogs, ... frogs if they are exposed to the virus ...
(Date:7/9/2014)... Allergy and Infectious Diseases (NIAID), part of the ... clinical trial of CRS3123, an investigational oral antibiotic ... C. difficile ) infection. CRS3123 (previously known as ... difficile growth while sparing normal intestinal bacteria. , ... 30 healthy men and women ages 18 to ...
(Date:7/9/2014)... poor printing on prescription labels handed out by ... errors in taking medication, according to new research ... National Institute for the Blind)., The study, published ... found that labels on prescription medications dispensed by ... for legibility. , By simply following recommended guidelines ...
Breaking Medicine News(10 mins):Health News:BU researchers relate arrests with HIV risk environment 2Health News:What drives a child to abuse alcohol? 2Health News:Study predicts ranavirus as potential new culprit in amphibian extinctions 2Health News:NIH launches Phase I clinical trial of novel drug to treat Clostridium difficile infection 2Health News:Most prescription labels fail to meet guidelines, risking dosage errors 2
... Services Outside of Houston PHOENIX, May 6 ... M. D. Anderson Cancer Center announced they will create the ... Arizona,s leading provider of health care and the nation,s leading ... unprecedented level of cancer care in Arizona.Located at US 60 ...
... May 6 The healthcare industry in ... inequalities in access to care. The public ... of the population, yet accounts for around ... http://www.newscom.com/cgi-bin/prnh/20081117/FSLOGO )Public-private partnerships offer an innovative means ...
... wife Ellen honored for generous contribution to New York University College ... ... Dr. Jan Linhart, D.D.S. and his wife, Ellen Linhart, have established ... Program at Dr. Linhart’s alma mater. In honor of this act ...
... with a humanitarian award at a glittering ceremony in London last night. ... ... of the world,s largest hospital ship charity were honored with a humanitarian ... , , ,The annual Variety Club International Humanitarian Award , whose ...
... Max Muscle Sports Nutrition,s newest product innovation is L-Tox, for advanced ... along with protective and regenerative factors. , ... Anaheim, ... Administration (FDA) www.fda.gov issued a stop product use directive ...
... small non-profit Ohio Biotech firm, has confirmed that they have decoded ... currently reported Swine Flu outbreak. , ... Albany, Ohio ... of infection and the first reported American death from the new ...
Cached Medicine News:Health News:Banner Health, M. D. Anderson Announce Cancer Care Facility for Arizona 2Health News:Banner Health, M. D. Anderson Announce Cancer Care Facility for Arizona 3Health News:South Africa not Gaining the Full Benefit of PPPs in the Healthcare Sector, Says Frost & Sullivan 2Health News:South Africa not Gaining the Full Benefit of PPPs in the Healthcare Sector, Says Frost & Sullivan 3Health News:Manhattan Dentist Inducted Into The Sir Harold Acton Society 2Health News:Mercy Ships Founders Receive Humanitarian of the Year Award From Variety Club 2Health News:Mercy Ships Founders Receive Humanitarian of the Year Award From Variety Club 3Health News:Mercy Ships Founders Receive Humanitarian of the Year Award From Variety Club 4Health News:Max Muscle Sports Nutrition Offers Support for Hydroxycut Recall 2Health News:Max Muscle Sports Nutrition Offers Support for Hydroxycut Recall 3Health News:BioTech Firm Decodes Current Swine Flu BioMarkers 2Health News:BioTech Firm Decodes Current Swine Flu BioMarkers 3
Full Handle Laseredge Implant Blade Knife, 5.2 mm straight. Blade dimension: 16.5 mm x 5.2 mm x 4.2 mm x 1.6 mm....
Full Handle Laseredge Crescent Blade Knife, angled bevel down. Blade tip dimension: 12.7 mm x 2.0 mm x 3.8 mm....
Full Handle Laseredge Crescent Blade Knife, angled bevel up. Blade tip dimension: 12.7 mm x 2.0 mm x 3.8 mm....
Full Handle Laseredge Stab Blade Knife, 22.5 blade. Blade tip dimension: 10.7 mm x 1.8 mm x 4.2 mm....
Medicine Products: